Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benchmarking Institutional Support for Point-of-Care Testing Programs: Scale, Staffing, and Operational Challenges.

The journal of applied laboratory medicine·2026
Same author

Quantra Qstat reference range validation in third trimester uncomplicated pregnancy at time of delivery.

Clinical chemistry and laboratory medicine·2026
Same author

Over-the-Counter Loperamide Overdose Resulting in Cardiac Arrest.

JACC. Case reports·2026
Same author

Changing Chemistry Instruments? Don't Forget to Ask These Questions.

The journal of applied laboratory medicine·2026
Same author

ADLM Guidance Document on Coagulation Testing in Patients Using Direct Oral Anticoagulants.

The journal of applied laboratory medicine·2025
Same author

Risk vs Prevalence: Weighing Routine DPYD Variant Testing Prior to Fluoropyrimidine-Based Chemotherapy.

Clinical chemistry·2025

Related Experiment Video

Updated: May 12, 2026

The Successive Alleys Test of Anxiety in Mice and Rats
05:05

The Successive Alleys Test of Anxiety in Mice and Rats

Published on: June 17, 2013

Testing Strategies and the Emergence of Designer Benzodiazepines.

Lindsay A L Bazydlo1, Nicholas E Larkey1

  • 1Department of Pathology, University of Virginia, Hospital Dr, Charlottesville, VA 22910, USA.

Clinics in Laboratory Medicine
|May 10, 2025
PubMed
Summary

Designer benzodiazepines (DBZDs) are emerging synthetic drugs with rising popularity. Mass spectrometry is crucial for identifying these drugs due to their structural similarity to traditional benzodiazepines.

Keywords:
BromazolamDesigner benzodiazepines (DBZDs)EtizolamMass spectrometryNovel psychoactive substance (NPS)Urine drug screen

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Related Experiment Videos

Last Updated: May 12, 2026

The Successive Alleys Test of Anxiety in Mice and Rats
05:05

The Successive Alleys Test of Anxiety in Mice and Rats

Published on: June 17, 2013

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Area of Science:

  • Forensic Chemistry
  • Toxicology
  • Pharmacology

Background:

  • Designer benzodiazepines (DBZDs) have increased in prevalence since the late 2000s.
  • Their popularity fluctuates with legislative changes concerning production and distribution.
  • The clandestine nature and unique toxicology of DBZDs pose significant public health risks.

Purpose of the Study:

  • To review the current analytical methodologies for designer benzodiazepines.
  • To highlight the challenges in distinguishing DBZDs from prescribed benzodiazepines.
  • To emphasize the necessity of advanced detection techniques.

Main Methods:

  • Discussion of immunoassay-based screening limitations.
  • Focus on mass spectrometry techniques for accurate identification.
  • Review of current analytical approaches in the field.

Main Results:

  • Immunoassays lack specificity for differentiating DBZDs from benzodiazepines.
  • Mass spectrometry-based methods are essential for reliable identification and discrimination.
  • Current analytical landscape for DBZD detection is evolving.

Conclusions:

  • Accurate identification of DBZDs requires sophisticated analytical methods.
  • Mass spectrometry is the gold standard for DBZD analysis.
  • Continued research into analytical techniques is vital for public safety.